Quantbot Technologies LP Buys New Position in LivaNova PLC (NASDAQ:LIVN)

Quantbot Technologies LP purchased a new position in LivaNova PLC (NASDAQ:LIVN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 37,761 shares of the company’s stock, valued at approximately $1,984,000. Quantbot Technologies LP owned approximately 0.07% of LivaNova as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. The Manufacturers Life Insurance Company raised its position in shares of LivaNova by 286.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock valued at $10,889,000 after purchasing an additional 153,611 shares during the last quarter. Algert Global LLC raised its holdings in shares of LivaNova by 81.0% in the third quarter. Algert Global LLC now owns 105,017 shares of the company’s stock worth $5,518,000 after buying an additional 47,008 shares during the last quarter. Cerity Partners LLC acquired a new stake in shares of LivaNova during the third quarter worth $573,000. Charles Schwab Investment Management Inc. grew its holdings in shares of LivaNova by 17.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company’s stock valued at $32,678,000 after buying an additional 93,311 shares during the last quarter. Finally, Intech Investment Management LLC increased its position in shares of LivaNova by 80.4% in the 3rd quarter. Intech Investment Management LLC now owns 15,815 shares of the company’s stock valued at $831,000 after acquiring an additional 7,049 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Up 3.5 %

Shares of NASDAQ LIVN opened at $52.48 on Friday. The firm has a market cap of $2.85 billion, a price-to-earnings ratio of 124.95 and a beta of 1.01. The company’s 50-day simple moving average is $52.24 and its 200-day simple moving average is $52.30. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 52-week low of $42.75 and a 52-week high of $64.47.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Robert W. Baird lifted their price target on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 price target on the stock. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Monday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.